中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝性脑病的肠道菌群调节及饮食治疗途径

乐滢玉 张荣臻 肖伟松 覃小宾 曾胜澜 毛德文

乐滢玉, 张荣臻, 肖伟松, 等. 肝性脑病的肠道菌群调节及饮食治疗途径[J]. 临床肝胆病杂志, 2021, 37(7): 1694-1698. DOI: 10.3969/j.issn.1001-5256.2021.07.046
引用本文: 乐滢玉, 张荣臻, 肖伟松, 等. 肝性脑病的肠道菌群调节及饮食治疗途径[J]. 临床肝胆病杂志, 2021, 37(7): 1694-1698. DOI: 10.3969/j.issn.1001-5256.2021.07.046
LE YY, ZHANG RZ, XIAO WS, et al. Gut microbiota regulation and diet therapy for hepatic encephalopathy[J]. J Clin Hepatol, 2021, 37(7): 1694-1698. DOI: 10.3969/j.issn.1001-5256.2021.07.046
Citation: LE YY, ZHANG RZ, XIAO WS, et al. Gut microbiota regulation and diet therapy for hepatic encephalopathy[J]. J Clin Hepatol, 2021, 37(7): 1694-1698. DOI: 10.3969/j.issn.1001-5256.2021.07.046

肝性脑病的肠道菌群调节及饮食治疗途径

DOI: 10.3969/j.issn.1001-5256.2021.07.046
基金项目: 

国家自然科学基金面上项目 81774236

国家自然科学基金项目 81960841

广西自然科学基金课题 2018GXNSFAA281096

广西科技计划项目-广西科技基地和人才专项 Guike AD17129001

广西研究生教育创新计划资助项目 YCXJ2021038

详细信息
    通讯作者:

    毛德文,mdwboshi2005@163.com

  • 中图分类号: R575

Gut microbiota regulation and diet therapy for hepatic encephalopathy

Funds: 

National Natural Science Foundation of China(General Program) 81774236

National Natural Science Foundation of China 81960841

Natural Science Foundation of Guangxi 2018GXNSFAA281096

Guangxi Science and Technology Plan Project - Guangxi Science and Technology Base and Talents Special Project Guike AD17129001

Guangxi Postgraduate Education Innovation Program YCXJ2021038

  • 摘要: 肝性脑病(HE)在很大程度上增加了肝病患者的经济负担,严重影响了患者的生活质量。HE病理基础复杂且影响因素繁多,发病机理尚未完全明晰。其临床治疗尚无特异有效的方法,药物治疗临床疗效欠佳,许多药物耐受性差、依从性低,不良反应普遍。就HE的蛋白质类食物和调节肠道菌群的药物治疗途径进行分析与归纳,以期为HE临床治疗提供新思路及优质方案。

     

  • [1] American Association for the Study of Liver Diseases; European Association for the Study of the Liver. Hepatic encephalopathy in chronic liver disease: 2014 practice guideline by the European Association for the Study of the Liver and the American Association for the Study of Liver Diseases[J]. J Hepatol, 2014, 61(3): 642-659. DOI: 10.1016/j.jhep.2014.05.042.
    [2] RIDOLA L, CARDINALE V, RIGGIO O. The burden of minimal hepatic encephalopathy: From diagnosis to therapeutic strategies[J]. Ann Gastroenterol, 2018, 31(2): 151-164. DOI: 10.20524/aog.2018.0232.
    [3] RIDOLA L, NARDELLI S, GIOIA S, et al. Quality of life in patients with minimal hepatic encephalopathy[J]. World J Gastroenterol, 2018, 24(48): 5446-5453. DOI: 10.3748/wjg.v24.i48.5446.
    [4] ZHANG JC, WANG YG, LIN F, et al. The pathogenesis of hepatic encephalopathy[J/CD]. Chin J Liver Dis (Electronic Version), 2019, 11(1): 6-11. DOI: 10.3969/j.issn.1674-7380.2019.01.002.

    张军昌, 王永刚, 林芳, 等. 肝性脑病发病机制新进展[J/CD]. 中国肝脏病杂志(电子版), 2019, 11(1): 6-11. DOI: 10.3969/j.issn.1674-7380.2019.01.002.
    [5] YAN ML, ZHANG Z, QIN YP, et al. progress of drug therapy for hepatic encephalopathy[J]. Tianjin Pharmacy, 2019, 31(3): 55-59. DOI: 10.3969/j.issn.1006-5687.2019.03.019.

    闫美玲, 张正, 秦寅鹏, 等. 肝性脑病的药物治疗研究进展[J]. 天津药学, 2019, 31(3): 55-59. DOI: 10.3969/j.issn.1006-5687.2019.03.019.
    [6] JAWARO T, YANG A, DIXIT D, et al. Management of hepatic encephalopathy: A primer[J]. Ann Pharmacother, 2016, 50(7): 569-577. DOI: 10.1177/1060028016645826.
    [7] SHARMA P, SHARMA BC. Lactulose for minimal hepatic encephalopathy in patients with extrahepatic portal vein obstruction[J]. Saudi J Gastroenterol, 2012, 18(3): 168-172. DOI: 10.4103/1319-3767.96448.
    [8] European Association for the Study of the Liver. EASL clinical practice guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019, 70(1): 172-193. DOI: 10.1016/j.jhep.2018.06.024.
    [9] PLAUTH M, BERNAL W, DASARATHY S, et al. ESPEN guideline on clinical nutrition in liver disease[J]. Clin Nutr, 2019, 38(2): 485-521. DOI: 10.1016/j.clnu.2018.12.022.
    [10] PEARLMAN M, AKPOTAIRE O. Diet and the role of food in common gastrointestinal diseases[J]. Med Clin North Am, 2019, 103(1): 101-110. DOI: 10.1016/j.mcna.2018.08.008.
    [11] SUMMERSKILL WH, WOLFE SJ, DAVIDSON CS. The management of hepatic coma in relation to protein withdrawal and certain specific measures[J]. Am J Med, 1957, 23(1): 59-76. DOI: 10.1016/0002-9343(57)90358-3.
    [12] CÓRDOBA J, LÓPEZ-HELLÍN J, PLANAS M, et al. Normal protein diet for episodic hepatic encephalopathy: Results of a randomized study[J]. J Hepatol, 2004, 41(1): 38-43. DOI: 10.1016/j.jhep.2004.03.023.
    [13] FENTON JC, KNIGHT EJ, HUMPHERSON PL. Milk-and-cheese diet in portal-systemic encephalopathy[J]. Lancet, 1966, 1(7430): 164-166. DOI: 10.1016/s0140-6736(66)90696-9.
    [14] CHATAURET N, DESJARDINS P, ZWINGMANN C, et al. Direct molecular and spectroscopic evidence for increased ammonia removal capacity of skeletal muscle in acute liver failure[J]. J Hepatol, 2006, 44(6): 1083-1088. DOI: 10.1016/j.jhep.2005.11.048.
    [15] CLEMMESEN JO, KONDRUP J, OTT P. Splanchnic and leg exchange of amino acids and ammonia in acute liver failure[J]. Gastroenterology, 2000, 118(6): 1131-1139. DOI: 10.1016/s0016-5085(00)70366-0.
    [16] KAWAGUCHI T, TANIGUCHI E, SATA M. Effects of oral branched-chain amino acids on hepatic encephalopathy and outcome in patients with liver cirrhosis[J]. Nutr Clin Pract, 2013, 28(5): 580-588. DOI: 10.1177/0884533613496432.
    [17] HOLECEK M. Ammonia and amino acid profiles in liver cirrhosis: Effects of variables leading to hepatic encephalopathy[J]. Nutrition, 2015, 31(1): 14-20. DOI: 10.1016/j.nut.2014.03.016.
    [18] DEJONG CH, van de POLL MC, SOETERS PB, et al. Aromatic amino acid metabolism during liver failure[J]. J Nutr, 2007, 137(6 Suppl 1): 1579s-1585s; discussion 1597S-1598S. DOI: 10.1093/jn/137.6.1579S.
    [19] GLUUD LL, DAM G, BORRE M, et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: What is the evidence?[J]. Metab Brain Dis, 2013, 28(2): 221-225. DOI: 10.1007/s11011-012-9372-0.
    [20] LES I, DOVAL E, GARCÍA-MARTÍNEZ R, et al. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: A randomized study[J]. Am J Gastroenterol, 2011, 106(6): 1081-1088. DOI: 10.1038/ajg.2011.9.
    [21] KIRCHEIS G, LVTH S. Pharmacokinetic and pharmacodynamic properties of L-Ornithine L-Aspartate (LOLA) in hepatic encephalopathy[J]. Drugs, 2019, 79(Suppl 1): 23-29. DOI: 10.1007/s40265-018-1023-2.
    [22] BUTTERWORTH RF, KIRCHEIS G, HILGER N, et al. Efficacy of l-Ornithine l-Aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: Systematic review and meta-analysis of randomized controlled trials[J]. J Clin Exp Hepatol, 2018, 8(3): 301-313. DOI: 10.1016/j.jceh.2018.05.004.
    [23] BUTTERWORTH RF, MCPHAIL M. L-Ornithine L-Aspartate (LOLA) for hepatic encephalopathy in cirrhosis: Results of randomized controlled trials and meta-analyses[J]. Drugs, 2019, 79(Suppl 1): 31-37. DOI: 10.1007/s40265-018-1024-1.
    [24] VARAKANAHALLI S, SHARMA BC, SRIVASTAVA S, et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis of liver: A double-blind randomized controlled trial of L-ornithine L-aspartate versus placebo[J]. Eur J Gastroenterol Hepatol, 2018, 30(8): 951-958. DOI: 10.1097/MEG.0000000000001137.
    [25] GOH ET, STOKES CS, SIDHU SS, et al. L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis[J]. Cochrane Database Syst Rev, 2018, 5(5): CD012410. DOI: 10.1002/14651858.CD012410.pub2.
    [26] STRAVITZ RT, GOTTFRIED M, DURKALSKI V, et al. Safety, tolerability, and pharmacokinetics of l-ornithine phenylacetate in patients with acute liver injury/failure and hyperammonemia[J]. Hepatology, 2018, 67(3): 1003-1013. DOI: 10.1002/hep.29621.
    [27] MARTÍNEZ GARCÍA RM, JIMÉNEZ ORTEGA AI, LÓPEZ SOBALER AM, et al. Nutrition strategies that improve cognitive function[J]. Nutr Hosp, 2018, 35(Spec No6): 16-19. DOI: 10.20960/nh.2281.
    [28] PERES WA, CHAVES GV, GONÇALVES JC, et al. Vitamin A deficiency in patients with hepatitis C virus-related chronic liver disease[J]. Br J Nutr, 2011, 106(11): 1724-1731. DOI: 10.1017/S0007114511002145.
    [29] KATAYAMA K, SAITO M, KAWAGUCHI T, et al. Effect of zinc on liver cirrhosis with hyperammonemia: A preliminary randomized, placebo-controlled double-blind trial[J]. Nutrition, 2014, 30(11-12): 1409-1414. DOI: 10.1016/j.nut.2014.04.018.
    [30] GUEVARA M, BACCARO ME, TORRE A, et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: A prospective study with time-dependent analysis[J]. Am J Gastroenterol, 2009, 104(6): 1382-1389. DOI: 10.1038/ajg.2009.293.
    [31] SHEN TD. Diet and gut microbiota in health and disease[J]. Nestle Nutr Inst Workshop Ser, 2017, 88: 117-126. DOI: 10.1159/000455220.
    [32] WOODHOUSE CA, PATEL VC, SINGANAYAGAM A, et al. Review article: The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease[J]. Aliment Pharmacol Ther, 2018, 47(2): 192-202. DOI: 10.1111/apt.14397.
    [33] GIBSON GR, HUTKINS R, SANDERS ME, et al. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(8): 491-502. DOI: 10.1038/nrgastro.2017.75.
    [34] PINZONE MR, CELESIA BM, di ROSA M, et al. Microbial translocation in chronic liver diseases[J]. Int J Microbiol, 2012, 2012: 694629. DOI: 10.1155/2012/694629.
    [35] CHEN C, LI L, WU Z, et al. Effects of lactitol on intestinal microflora and plasma endotoxin in patients with chronic viral hepatitis[J]. J Infect, 2007, 54(1): 98-102. DOI: 10.1016/j.jinf.2005.11.013.
    [36] STADLBAUER V, MOOKERJEE RP, HODGES S, et al. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis[J]. J Hepatol, 2008, 48(6): 945-951. DOI: 10.1016/j.jhep.2008.02.015.
    [37] LATA J, JURANKOVA J, KOPACOVA M, et al. Probiotics in hepatology[J]. World J Gastroenterol, 2011, 17(24): 2890-2896. DOI: 10.3748/wjg.v17.i24.2890.
    [38] LUNIA MK, SHARMA BC, SHARMA P, et al. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: A randomized controlled trial[J]. Clin Gastroenterol Hepatol, 2014, 12(6): 1003-1008. e1. DOI: 10.1016/j.cgh.2013.11.006.
    [39] DHIMAN RK, RANA B, AGRAWAL S, et al. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: A randomized, controlled trial[J]. Gastroenterology, 2014, 147(6): 1327-1337. e3. DOI: 10.1053/j.gastro.2014.08.031.
    [40] CAO Q, YU CB, YANG SG, et al. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis[J]. Hepatobiliary Pancreat Dis Int, 2018, 17(1): 9-16. DOI: 10.1016/j.hbpd.2018.01.005.
    [41] SAJI S, KUMAR S, THOMAS V. A randomized double blind placebo controlled trial of probiotics in minimal hepatic encephalopathy[J]. Trop Gastroenterol, 2011, 32(2): 128-132.
    [42] LIU Q, DUAN ZP, HA DK, et al. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis[J]. Hepatology, 2004, 39(5): 1441-1449. DOI: 10.1002/hep.20194.
    [43] BAJAJ JS, SAEIAN K, CHRISTENSEN KM, et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy[J]. Am J Gastroenterol, 2008, 103(7): 1707-1715. DOI: 10.1111/j.1572-0241.2008.01861.x.
    [44] LIU JE, ZHANG Y, ZHANG J, et al. Probiotic yogurt effects on intestinal flora of patients with chronic liver disease[J]. Nurs Res, 2010, 59(6): 426-432. DOI: 10.1097/NNR.0b013e3181fa4dc6.
    [45] CAMPION D, PONZO P, ALESSANDRIA C, et al. The role of microbiota in autism spectrum disorders[J]. Minerva Gastroenterol Dietol, 2018, 64(4): 333-350. DOI: 10.23736/S1121-421X.18.02493-5.
    [46] PIWOWARCZYK A, HORVATH A, ŁUKASIK J, et al. Gluten- and casein-free diet and autism spectrum disorders in children: A systematic review[J]. Eur J Nutr, 2018, 57(2): 433-440. DOI: 10.1007/s00394-017-1483-2.
    [47] BALZOLA F, SANNA C, OTTOBRELLI A, et al. Chronic hepatic encephalopaty (HE) in patients with severe liver cirrhosis: Efficacy of the wheat and milk protein free diet in the reduction of clinical episodes[J]. J Hepatol, 2011, 54: s64. DOI: 10.1016/S0168-8278(11)60148-7.
    [48] WANG WW, ZHANG Y, HUANG XB, et al. Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-induced acute hepatic dysfunction[J]. World J Gastroenterol, 2017, 23(38): 6983-6994. DOI: 10.3748/wjg.v23.i38.6983.
    [49] BAJAJ JS, KASSAM Z, FAGAN A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial[J]. Hepatology, 2017, 66(6): 1727-1738. DOI: 10.1002/hep.29306.
    [50] BAJAJ JS, FAGAN A, GAVIS EA, et al. Long-term outcomes of fecal microbiota transplantation in patients with cirrhosis[J]. Gastroenterology, 2019, 156(6): 1921-1923. e3. DOI: 10.1053/j.gastro.2019.01.033.
    [51] DEFILIPP Z, BLOOM PP, TORRES SOTO M, et al. Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant[J]. N Engl J Med, 2019, 381(21): 2043-2050. DOI: 10.1056/NEJMoa1910437.
  • 加载中
计量
  • 文章访问数:  49
  • HTML全文浏览量:  10
  • PDF下载量:  26
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-12-18
  • 修回日期:  2021-02-08
  • 刊出日期:  2021-07-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回